157 related articles for article (PubMed ID: 35581455)
1. Time for Pharmacy Co-dispensing of Naloxone with Prescribed Opioids?
Wunderlich JR; Engelberg RS; Tofighi B; Schwartz MD
J Gen Intern Med; 2022 Aug; 37(11):2621-2623. PubMed ID: 35581455
[No Abstract] [Full Text] [Related]
2. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
3. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
4. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis.
Antoniou T; Martins D; Campbell T; Tadrous M; Munro C; Leece P; Mamdani M; Juurlink DN; Gomes T
Addiction; 2021 Jun; 116(6):1514-1520. PubMed ID: 33207025
[TBL] [Abstract][Full Text] [Related]
5. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
[TBL] [Abstract][Full Text] [Related]
6. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis.
Antoniou T; McCormack D; Campbell T; Sutradhar R; Tadrous M; Lum-Wilson N; Leece P; Munro C; Gomes T
Drug Alcohol Depend; 2020 Nov; 216():108238. PubMed ID: 32891910
[TBL] [Abstract][Full Text] [Related]
7. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
8. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
9. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
[TBL] [Abstract][Full Text] [Related]
10. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
11. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
12. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
14. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
[TBL] [Abstract][Full Text] [Related]
15. A pilot evaluation of incorporating "opt-out" naloxone dispensing within a chain community pharmacy.
Skoy E
Res Social Adm Pharm; 2019 Aug; 15(8):1043-1046. PubMed ID: 30473398
[No Abstract] [Full Text] [Related]
16. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
Eldridge LA; Meyerson BE; Agley J
J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
[TBL] [Abstract][Full Text] [Related]
17. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
[TBL] [Abstract][Full Text] [Related]
18. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]